文献速递肝胆胰外科胃肠外科

新辅助治疗后解剖与组织学反应:不良反应者的复发模式——多机构观察性队列研究

Anatomical and Histologic Response to Neoadjuvant Therapy: Recurrence Patterns Among Poor Responders. A Multi-institutional Observational Cohort Study.
PubMed 文献 · Ann Surg · 2026-07-20

该多机构观察性队列研究纳入2004—2022年新辅助治疗后行治愈性肝切除的结直肠癌肝转移患者483例,整合肿瘤负荷评分比值(TBSr)评估的解剖学反应与肿瘤消退分级(TRG)评估的组织学反应。结果显示TRG与TBSr均独立关联无复发生存期(RFS)恶化,联合TRG-TBSr风险分组与RFS、早期复发及肝内复发均强相关。

要点

  • TRG与TBSr均独立预测RFS恶化,联合分组可分层复发风险。
  • 早期复发占36.9%,与TRG、TBSr及同时性病变独立相关。
  • 肝内复发占25.1%,可由TRG与TBSr预测。

核心结论

  • 联合解剖学与组织学反应可为CRLM肝切除后复发风险提供简单、可解释且具生物学意义的分层框架。

研究设计与样本

  • 国际多机构观察性队列研究,纳入2004—2022年新辅助治疗后行治愈性肝切除的CRLM患者483例。
  • 解剖学反应以TBSr分类,组织学反应以TRG分类(良好1—3,不良4—5),联合模式经最大选择log-rank统计折叠为3个风险组。

主要发现

  • 中位RFS为15.87个月。
  • TRG(aHR 1.22,95%CI 1.12—1.33)与TBSr(aHR 1.30,95%CI 1.12—1.52)均独立关联RFS恶化(均P<0.001)。
  • 早期复发占36.9%,独立关联TRG(OR 1.34,95%CI 1.15—1.57,P<0.001)、TBSr(OR 1.35,95%CI 1.03—1.80,P=0.0036)及同时性病变(OR 1.85,95%CI 1.21—2.87,P=0.005)。
  • 肝内复发占25.1%,由TRG(HR 1.36,95%CI 1.15—1.61)与TBSr(HR 1.59,95%CI 1.31—1.93)预测(均P<0.001)。
  • 整合TRG-TBSr风险分类与RFS、早期复发及肝内复发均强相关(均P<0.001)。

临床怎么用

  • 对新辅助治疗后CRLM肝切除患者,可联合TRG与TBSr评估复发风险并分层随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the prognostic implications after hepatectomy for colorectal liver metastases (CRLM) by integrating anatomical response to neoadjuvant therapy (NAT), quantified using the Tumor Burden Score ratio (TBSr), with histologic response assessed by Tumor Regression Grade (TRG). BACKGROUND: Accurate assessment of response to NAT is central to the management of CRLM. While both macroscopic and histologic tools exist, their combined ability to characterize recurrence patterns remains poorly defined. METHODS: Patients undergoing curative-intent hepatectomy for CRLM after NAT (2004-2022) were identified from an international, multi-institutional database. Macroscopic response was classified using TBSr with data-driven and prespecified cutoffs, while TRG histologic regression was categorized as good (1-3) or poor (4-5). Six combined TRG-TBSr patterns were collapsed into 3 risk groups using maximally selected log-rank statistics. Primary outcomes were recurrence-free survival (RFS) and timing of recurrence (early <12 mo; late ≥12 mo); liver-limited recurrence was a secondary outcome. RESULTS: Among 483 patients, median RFS was 15.87 months. Both TRG (aHR: 1.22, 95% CI: 1.12-1.33) and TBSr (aHR: 1.30, 95% CI: 1.12-1.52) were independently associated with worse RFS (both P <0.001). Early recurrence occurred in 36.9% of patients and was independently associated with TRG (OR: 1.34, 95% CI: 1.15-1.57, P <0.001), TBSr (OR: 1.35, 95% CI: 1.03-1.80, P =0.0036), and synchronous disease (OR: 1.85, 95% CI: 1.21-2.87, P =0.005). Intrahepatic recurrence occurred in 25.1% of patients and was predicted by TRG (hazard ratio: 1.36, 95% CI: 1.15-1.61) and TBSr (hazard ratio: 1.59, 95% CI: 1.31-1.93) (both <0.001). The integrated TRG-TBSr risk categories were strongly associated with RFS, early recurrence, and intrahepatic recurrence (all P <0.001). CONCLUSIONS: Combined anatomical and histologic response provided a simple, interpretable, and biologically meaningful framework to stratify recurrence risk after hepatectomy for CRLM.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Baldo A, Akabane M, Elemosho A, et al. Anatomical and Histologic Response to Neoadjuvant Therapy: Recurrence Patterns Among Poor Responders. A Multi-institutional Observational Cohort Study. Ann Surg. 2026. PMID: 42473131. doi:10.1097/SLA.0000000000007154

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。